Incensus Pharma IvS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  16.3% 18.3% 18.6% 17.7% 15.4%  
Credit score (0-100)  13 9 8 9 12  
Credit rating  BB B B B BB  
Credit limit (kDKK)  -0.0 -0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Gross profit  -1.5 -1.3 -1.3 -1.5 -1.5  
EBITDA  -1.5 -1.3 -1.3 -1.5 -1.5  
EBIT  -1.5 -1.3 -1.3 -1.5 -1.5  
Pre-tax profit (PTP)  -1.5 -1.3 -1.4 -1.6 -1.5  
Net earnings  -1.5 -1.3 -1.4 -1.6 -1.5  
Pre-tax profit without non-rec. items  -1.5 -1.3 -1.4 -1.6 -1.5  

 
See the entire income statement

Balance sheet (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -1.5 -2.8 -4.1 -5.7 -7.2  
Interest-bearing liabilities  0.0 1.3 2.6 4.2 5.7  
Balance sheet total (assets)  0.0 0.0 0.0 0.0 0.0  

Net Debt  -0.0 1.3 2.6 4.2 5.7  
 
See the entire balance sheet

Volume 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -1.5 -1.3 -1.3 -1.5 -1.5  
Gross profit growth  0.0% 16.7% 0.0% -18.7% -1.1%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 0 0  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% 0.0%  
Added value  -1.5 -1.3 -1.3 -1.5 -1.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 -3.0 -4.0 -5.0  

Profitability 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -100.0% -29.3% -18.1% -15.0% -11.5%  
ROI %  0.0% -98.3% -32.1% -21.6% -15.0%  
ROE %  -37,500.0% -15,887.5% -16,900.0% -20,312.5% -18,750.0%  

Solidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Equity ratio %  -99.7% -99.9% -99.9% -99.9% -99.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.3% -101.4% -209.5% -286.0% -382.9%  
Gearing %  0.0% -45.9% -63.7% -74.0% -79.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 3.3% 5.2% 4.1% 0.0%  

Liquidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Quick Ratio  0.0 0.0 0.0 0.0 0.0  
Current Ratio  0.0 0.0 0.0 0.0 0.0  
Cash and cash equivalent  0.0 0.0 0.0 0.0 0.0  

Capital use efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -1.5 -2.8 -4.1 -5.7 -7.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0